JP2025510942A5 - - Google Patents
Info
- Publication number
- JP2025510942A5 JP2025510942A5 JP2024557455A JP2024557455A JP2025510942A5 JP 2025510942 A5 JP2025510942 A5 JP 2025510942A5 JP 2024557455 A JP2024557455 A JP 2024557455A JP 2024557455 A JP2024557455 A JP 2024557455A JP 2025510942 A5 JP2025510942 A5 JP 2025510942A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- indole
- amine
- pharmaceutical composition
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263362258P | 2022-03-31 | 2022-03-31 | |
| US63/362,258 | 2022-03-31 | ||
| PCT/EP2023/058107 WO2023186963A1 (en) | 2022-03-31 | 2023-03-29 | Combination of nitrous oxide and 5-ht2a receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025510942A JP2025510942A (ja) | 2025-04-15 |
| JP2025510942A5 true JP2025510942A5 (enExample) | 2026-04-06 |
Family
ID=86007250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024557455A Pending JP2025510942A (ja) | 2022-03-31 | 2023-03-29 | 亜酸化窒素及び５－ｈｔ２ａ受容体作動薬の組み合わせ |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4499087A1 (enExample) |
| JP (1) | JP2025510942A (enExample) |
| AU (1) | AU2023242469A1 (enExample) |
| CA (1) | CA3247035A1 (enExample) |
| WO (1) | WO2023186963A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023539113A (ja) | 2020-08-18 | 2023-09-13 | サイビン アイアールエル リミテッド | フェネチルアミン誘導体、組成物およびその使用方法 |
| EP4396162A4 (en) | 2021-09-03 | 2025-11-12 | Alexander Shulgin Res Institute Inc | ASYMMETRIC ALLYL TRYPTAMINES |
| WO2024108195A1 (en) | 2022-11-17 | 2024-05-23 | Remedi, Inc. | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use |
| KR20260003282A (ko) * | 2023-05-05 | 2026-01-06 | 사이빈 아이알엘 리미티드 | 주사식 약학적 제형 |
| TW202519206A (zh) * | 2023-11-06 | 2025-05-16 | 大陸商宜昌人福藥業有限責任公司 | 一種n,n-二甲基色胺衍生物及其藥物組合物、製備方法和用途 |
| WO2025099725A1 (en) * | 2023-11-09 | 2025-05-15 | Hadasit Medical Research Services And Development Ltd. | Conjugates and uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| DE4023108C1 (enExample) | 1990-07-20 | 1992-02-13 | Ems Gmbh, 8520 Moehrendorf, De | |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| US6488648B1 (en) | 1999-01-14 | 2002-12-03 | Teijin Limited | Device for feeding a powder in a predetermined amount and method thereof |
| GB0121568D0 (en) | 2001-09-06 | 2001-10-24 | Optinose As | Nasal delivery device |
| NZ514442A (en) | 1999-03-03 | 2003-08-29 | Optinose As | Nasal delivery device |
| GB0114272D0 (en) | 2001-06-12 | 2001-08-01 | Optinose As | Nasal delivery device |
| GB0019715D0 (en) | 2000-08-10 | 2000-09-27 | Pa Consulting Services | Device for delivering physiologically active agent in powdered form |
| ZA200306564B (en) | 2001-02-26 | 2004-10-15 | Optinose As | Nasal devices. |
| AU2002340083A1 (en) | 2001-09-28 | 2003-04-07 | Kurve Technology, Inc | Nasal nebulizer |
| GB0207422D0 (en) | 2002-03-28 | 2002-05-08 | Optinose As | Nasal devices |
| GB0207817D0 (en) | 2002-04-04 | 2002-05-15 | Optinose As | Nasal devices |
| GB0209494D0 (en) | 2002-04-25 | 2002-06-05 | Optinose As | Nasal devices |
| US7267121B2 (en) | 2004-04-20 | 2007-09-11 | Aerogen, Inc. | Aerosol delivery apparatus and method for pressure-assisted breathing systems |
| US8826905B2 (en) | 2007-06-01 | 2014-09-09 | Ramses Nashed | Respiratory face mask and breathing circuit assembly |
| US20100192947A1 (en) | 2009-02-04 | 2010-08-05 | Jeff Mandel | Anesthetic delivery system and methods of use |
| AU2011217687B2 (en) | 2010-02-22 | 2013-05-09 | Class 1 Inc. | Apparatus, systems and methods for collecting and reclaiming anaesthetic agents and for removing nitrous oxide from exhaust gases |
| EP2589403B1 (en) | 2011-05-31 | 2016-02-03 | Ishikita, Naoyuki | Anesthetic inhalation-assisting device |
| KR20220008824A (ko) * | 2019-04-17 | 2022-01-21 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 |
| WO2021116503A2 (en) * | 2020-06-02 | 2021-06-17 | Small Pharma Ltd | Deuterated compounds |
| RU199823U1 (ru) | 2020-06-10 | 2020-09-21 | Общество С Ограниченной Ответственностью "Центр Передовых Радиационных Медицинских И Биологических Технологий | Устройство для лечения бронхолегочных заболеваний |
-
2023
- 2023-03-29 AU AU2023242469A patent/AU2023242469A1/en active Pending
- 2023-03-29 EP EP23717049.3A patent/EP4499087A1/en active Pending
- 2023-03-29 CA CA3247035A patent/CA3247035A1/en active Pending
- 2023-03-29 JP JP2024557455A patent/JP2025510942A/ja active Pending
- 2023-03-29 WO PCT/EP2023/058107 patent/WO2023186963A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Research advances in the clinical application of esketamine | |
| Chia et al. | Role of β-blockade in anaesthesia and postoperative pain management after hysterectomy | |
| JP2023544724A5 (enExample) | ||
| JP2013544850A5 (enExample) | ||
| EP4221682A2 (en) | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods | |
| CN106562952B (zh) | 氯胺酮在治疗重性抑郁障碍中的应用 | |
| US20100196286A1 (en) | Inhalation delivery methods and devices | |
| JP2013537887A5 (enExample) | ||
| JP2005539068A5 (enExample) | ||
| JP2024522065A5 (enExample) | ||
| JP5842058B2 (ja) | 自閉症の治療における使用のためのクレンブテロール | |
| JP2015505303A5 (enExample) | ||
| KR20070083826A (ko) | 우울증을 위한 부가 요법 | |
| Johnston et al. | Esketamine in depression: putative biomarkers from clinical research | |
| RU2020125170A (ru) | Композиции и способы улучшения биодоступности 5-гидрокситриптофана | |
| JP2012518019A5 (enExample) | ||
| US20180177744A1 (en) | Method of treating pain and depression using a hybrid mixture of s-ketamine and r-ketamine | |
| EP2696871B1 (en) | Aclidinium for use in improving the quality of sleep in respiratory patients. | |
| JP2020506930A (ja) | ベタヒスチンを含む鼻腔内組成物 | |
| JP2007523052A (ja) | 鬱病の処置のための蘇生薬モダフィニルおよび抗鬱薬の組み合わせ | |
| JP2011516604A (ja) | 鬱病患者の自殺行動の予防治療のためのミルナシプラン塩酸塩の（１ｓ，２ｒ）鏡像異性体の使用 | |
| Ladha et al. | Sustained mood improvement with laughing gas exposure (SMILE): a randomised, placebo-controlled pilot trial of nitrous oxide for treatment-resistant depression | |
| JP6346618B2 (ja) | アクリジニウムの新規用途 | |
| Saxena et al. | Comparison of nebulized ropivacaine (0.75%) with nebulized dexmedetomidine on the hemodynamic response on intubation in patients undergoing surgery under general anesthesia: A comparative randomized double-blind placebo-controlled study | |
| WO2008035177A2 (en) | Combination of mt1 and mt2 melatonin receptor agonists and a norepinephrine/dopamine reuptake inhibitor |